MOUNTAIN VIEW, CALIF., June 18 /PRNewswire/ -- MAP Pharmaceuticals, Inc. announced today that it has filed a registration statement on Form S-1 with the Securities and Exchange Commission (“SEC”) relating to the proposed initial public offering of shares of its common stock. The number of shares to be offered and the price range for the offering have not yet been determined. The shares of common stock to be sold in this offering are proposed to be sold by MAP Pharmaceuticals.
Merrill Lynch & Co. and Morgan Stanley & Co. Incorporated are joint book-running managers for the offering. Deutsche Bank Securities Inc. is co-lead manager. This offering will be made only by means of a prospectus. Copies of the preliminary prospectus for this offering may be obtained, when available, from Merrill Lynch & Co., 4 World Financial Center, 250 Vesey Street, New York, NY 10080, or from Morgan Stanley & Co. Incorporated, 180 Varick Street, New York, NY 10014, Attn: Prospectus Department or by email at prospectus@morganstanley.com.
A registration statement relating to these securities has been filed with the SEC but has not yet become effective. This registration statement is available on the SEC’s website at edgar.sec.gov. These securities may not be sold nor may offers to buy be accepted prior to the time the registration statement becomes effective. This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of these securities in any state in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state.
Source: MAP Pharmaceuticals, Inc.
